Search

Displaying results 2021 - 2030 of 10000 in total
  1. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha). … It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult

  2. Drug

    TRC093

    go.drugbank.com/drugs/DB06356
    Investigational

    TRC093 is a recombinant humanized IgG1k monoclonal antibody.

  3. Drug

    rsPSMA Vaccine

    go.drugbank.com/drugs/DB06361
    ApprovedWithdrawn

    rsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003). … Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases.

  4. Drug

    XR5944

    go.drugbank.com/drugs/DB06364
    Experimental

    XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.

    Categories: Heterocyclic Compounds, 3-Ring
  5. Drug

    Sapacitabine

    go.drugbank.com/drugs/DB06365
    Investigational

    Synonyms: 1-(2-C-cyano-2-deoxy- ß-D-arabino-pentafuranosyl)-N4-palmitoylcytosineCategories: Heterocyclic Compounds, 1-Ring
  6. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    Alamifovir

    go.drugbank.com/drugs/DB06368
    Experimental

    Alamifovir is an antiviral agent specific for HBV.

    Categories: Heterocyclic Compounds, 2-Ring
  8. Drug

    Siplizumab

    go.drugbank.com/drugs/DB06371
    Investigational

  9. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. … Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative

  10. Drug

    NRP290

    go.drugbank.com/drugs/DB06383
    Experimental

    NRP290 is a hydrocodone derivative under investigation for the treatment of pain (moderate to moderately severe).